Hongwei Zhang1, Weijie Liu1, Xiaodong Han1, Haoyong Yu2, Pin Zhang3, Weiping Jia2. 1. Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. 2. Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Clinical Center of Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China. 3. Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. pin_zhang1963@126.com.
Abstract
OBJECTIVES: The study aimed to evaluate the changes in thyroid function and the risk of thyroid tumors after Roux-en-Y gastric bypass (RYGB) surgery. MATERIALS AND METHODS: This was a retrospective study of 117 patients with type 2 diabetes (T2D) and obesity who underwent laparoscopic RYGB (LRYGB) and were followed up for 36 months. Thyroids were examined with ultrasonography. Binary logistic regression analysis was used for predictors of thyroid tumors, and receiver operating characteristic curve determined cutoff points. RESULTS: Sixty-two patients (53.0%) were female. The mean age was 47.3 ± 11.8 years, and the mean follow-up duration was 36.4 ± 5.2 months. Fifty-one patients (43.6%) were diagnosed with thyroid nodules (TN) by ultrasonography before surgery. Overall, free triiodothyronine (FT3) and free thyroxine (FT4) levels decreased after LRYGB, while thyroid-stimulating hormone (TSH) levels remained stable, and all were within normal limits. Reduction in A1C was correlate with change in FT3 (P = 0.043) and FT4 (P = 0.001). Forty-one patients (35.0%) had TN or had progressive TN after LRYGB, while two patients were diagnosed with malignant tumors at 12 months. The preoperative body fat ratio and FT3/FT4 ratio were clinical predictors of TN progression. CONCLUSIONS: LRYGB effectively treated obese patients with T2D. Serum FT3 and FT4 levels decreased to within normal limits after LRYGB. Changes in TSH were not correlated with weight loss. Patients after LRYGB had a potential risk of thyroid nodule progression, preoperative high body fat ratios, or low FT3/FT4 ratios that had higher risks of TN.
OBJECTIVES: The study aimed to evaluate the changes in thyroid function and the risk of thyroid tumors after Roux-en-Y gastric bypass (RYGB) surgery. MATERIALS AND METHODS: This was a retrospective study of 117 patients with type 2 diabetes (T2D) and obesity who underwent laparoscopic RYGB (LRYGB) and were followed up for 36 months. Thyroids were examined with ultrasonography. Binary logistic regression analysis was used for predictors of thyroid tumors, and receiver operating characteristic curve determined cutoff points. RESULTS: Sixty-two patients (53.0%) were female. The mean age was 47.3 ± 11.8 years, and the mean follow-up duration was 36.4 ± 5.2 months. Fifty-one patients (43.6%) were diagnosed with thyroid nodules (TN) by ultrasonography before surgery. Overall, free triiodothyronine (FT3) and free thyroxine (FT4) levels decreased after LRYGB, while thyroid-stimulating hormone (TSH) levels remained stable, and all were within normal limits. Reduction in A1C was correlate with change in FT3 (P = 0.043) and FT4 (P = 0.001). Forty-one patients (35.0%) had TN or had progressive TN after LRYGB, while two patients were diagnosed with malignant tumors at 12 months. The preoperative body fat ratio and FT3/FT4 ratio were clinical predictors of TN progression. CONCLUSIONS: LRYGB effectively treated obesepatients with T2D. Serum FT3 and FT4 levels decreased to within normal limits after LRYGB. Changes in TSH were not correlated with weight loss. Patients after LRYGB had a potential risk of thyroid nodule progression, preoperative high body fat ratios, or low FT3/FT4 ratios that had higher risks of TN.
Authors: Cristiane M Moulin de Moraes; Marcio C Mancini; Maria Edna de Melo; Daniela Andraus Figueiredo; Sandra Mara F Villares; Alessandra Rascovski; Bruno Zilberstein; Alfredo Halpern Journal: Obes Surg Date: 2005-10 Impact factor: 4.129
Authors: Marina A Michalaki; Apostolos G Vagenakis; Aggeliki S Leonardou; Marianna N Argentou; Ioannis G Habeos; Maria G Makri; Agathoklis I Psyrogiannis; Fotis E Kalfarentzos; Venetsana E Kyriazopoulou Journal: Thyroid Date: 2006-01 Impact factor: 6.568
Authors: Evie P M Broeders; Guy H E J Vijgen; Bas Havekes; Nicole D Bouvy; Felix M Mottaghy; Marleen Kars; Nicolaas C Schaper; Patrick Schrauwen; Boudewijn Brans; Wouter D van Marken Lichtenbelt Journal: PLoS One Date: 2016-01-19 Impact factor: 3.240
Authors: María Cordido; Paula Juiz-Valiña; Paula Urones; Susana Sangiao-Alvarellos; Fernando Cordido Journal: J Clin Med Date: 2022-02-28 Impact factor: 4.241